Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 24Colorectal Neoplasms 16Small Cell Lung Carcinoma 6Stomach Neoplasms 5Neoplasms 4Neoplasm Metastasis 4Biliary Tract Neoplasms 4Sarcoma, Ewing 3Rhabdomyosarcoma 3Recurrence 3Rectal Neoplasms 3Osteosarcoma 3Ovarian Neoplasms 2Nasopharyngeal Carcinoma 2Glioma 2Glioblastoma 2Gastrointestinal Neoplasms 2Fallopian Tube Neoplasms 2Esophageal Neoplasms 2Cholangiocarcinoma 2Wilms Tumor 1Weight Loss 1Triple Negative Breast Neoplasms 1Somatostatinoma 1Solid Tumor Cancer 1Solid Tumor 1Small Cell Lung Cancer Extensive Stage 1Small Bowel Adenocarcinoma 1Sarcoma 1Rhabdoid Tumor 1

Interventions

camrelizumab 2apatinib 2trifluridine tipiracil drug combination 1tipiracil 1irinotecan sucrosofate 1Trifluridine 1S 1 (combination) 1Ramucirumab 1Docetaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Metastatic Gastric Adenocarcinoma × irinotecan sucrosofate × Clear all
NCT05927857 2026-04-09

Ramucirumab (Cyramza), Nal-IRI (ONIVYDE) and Trifluridine/Tipiracil (Lonsurf) in Second Line Metastatic Gastric Cancer .

National Health Research Institutes, Taiwan

Phase 1/2 Recruiting
45 enrolled
Gastrointestinal

Metastatic Gastric Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡